Jie Jin

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Acute Lymphoblastic Leukemia

Multiple Myeloma

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Huiqiang Huang, Rong Tao, Siguo Hao, Yu Yang, Hong Cen, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin, Liling Zhang, Haiyan Yang, Xiaojing Xing, Huilai Zhang, Yan-Yan Liu, Kaiyang Ding, Qinzhou Qi, Xiaoli Zhu, Dan Zhu, Siyuan Wang, Teng Fang, Hangjun Dai, Qingmei Shi, Jason Yang
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Diana Chen, Jordan M Schecter, Fan Yang, Xiaochen Tian, Huabin Sun, Sen Hong Zhuang, Jimmy Ren, Xiaohu Fan, Jie Jin, Ting Niu, Sai-Juan Chen
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Hongmei Jing, Li Yang, Junyuan Qi, Lugui Qiu, Chengcheng Fu, Junmin Li, Min Yang, Ming Qi, Ni Fan, Jia Ji, Jiajia Lu, Yunan Li, Jie Jin
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003). Annals of hematology 101 (12) (2022)
Stephen Samuel Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A Portell, Kirit M Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (23) (2021)
Gang An, Daobin Zhou, Shu Cheng, Keshu Zhou, Jianyong Li, Jian-Feng Zhou, Liping Xie, Jie Jin, Liye Zhong, Lingzhi Yan, Haiyi Guo, Chenmu Du, Jinhua Zhong, Yiling Yu, Binghao Wu, Lugui Qiu
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (20) (2021)